This Medudy course is a video tutorial for physicians on the topic of "Mirikizumab for the treatment of ulcerative colitis". The format used here is a so-called "Journal Club Summary", in which we summarize the latest and most clinically relevant studies for you.
Ulcerative colitis is a chronic inflammatory disease of the colon and rectum with currently limited therapeutic options. Interleukin-23 (IL-23) plays a central role in the pathogenesis of ulcerative colitis by driving chronic intestinal inflammation. Mirikizumab is a humanized monoclonal immunoglobulin G4 antibody that selectively binds to the p19 subunit of IL-23. In today's phase 3 studies LUCENT-1 for induction and LUCENT-2 for maintenance therapy, the efficacy and safety of mirikizumab were therefore further investigated in patients with moderate to severe ulcerative colitis.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
At the end of this course you will know
- the clinical background and relevance of the research question under investigation
- the study design and methodology of the publication to answer the research question
- the results and key takeaways of the publication
- the conclusion of the publication and possible limitations
